title: Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation.
abstract: Cardiopulmonary bypass causes hemorrhagic complications, and initiates a chemical and cellular inflammatory response. Contact of blood with synthetic surfaces leads to qualitative and quantitative alterations in platelets, neutrophils, complement, and contact systems. Despite the fact that cardiopulmonary bypass is carried out in the presence of high doses of heparin, there is significant activation of both platelets and neutrophils. Thrombin is protected on cell and fibrin surfaces from antithrombin, even in the presence of high doses of heparin (approximately 5 U/ml). We therefore studied the effect of a small (Mr = 497), highly effective (Ki = 41 pM), reversible tripeptide inhibitor of thrombin, DUP 714 (1 microM), in a well characterized model of simulated extracorporeal circulation. In the absence of DUP 714, platelet counts decreased by 75% 5 min after the start of extracorporeal bypass and increased to 48% at 120 min of recirculation. DUP 714 significantly preserved platelet counts, decreased plasma levels of platelet beta-thromboglobulin levels, but did not prevent a decrease in sensitivity of platelets to adenosine diphosphate. Kallikrein-C1-inhibitor and C1-C1-inhibitor complexes increased progressively from 0.32 U/ml to 0.67 U/ml and from 4.45 U/ml to 7.25 U/ml, respectively, during 120 min of recirculation without DUP 714. Addition of DUP 714 significantly inhibited kallikrein-C1-inhibitor complex formation but did not affect C1-C1-inhibitor complexes. In the absence of DUP 714, human neutrophil elastase levels rose from a baseline of 0.01 +/- 0.00 microg/ml to 1.18 +/- 0.21 microg/ml during 120 min of recirculation. Human neutrophil elastase release at 120 min was significantly inhibited in the presence of DUP 714 to 37% of the value with heparin alone. These results indicated that addition of this novel thrombin (and kallikrein) inhibitor to heparin preserved platelet counts, decreased platelet secretion, and provided the additional benefit of partially blocking neutrophil activation during simulated extracorporeal circulation.
authors.affiliation: Sol Sherry Thrombosis Research Center, Department of Medicine, Temple University School of Medicine, Philadelphia, PA, USA.
authors.forename: Y T
authors.initials: YT
authors.lastname: Wachtfogel
authors.forename: C
authors.initials: C
authors.lastname: Kettner
authors.forename: C E
authors.initials: CE
authors.lastname: Hack
authors.forename: J H
authors.initials: JH
authors.lastname: Nuijens
authors.forename: T M
authors.initials: TM
authors.lastname: Reilly
authors.forename: R M
authors.initials: RM
authors.lastname: Knabb
authors.forename: U
authors.initials: U
authors.lastname: Kucich
authors.forename: S
authors.initials: S
authors.lastname: Niewiarowski
authors.forename: L H
authors.initials: LH
authors.lastname: Edmunds
authors.forename: R W
authors.initials: RW
authors.lastname: Colman
mesh_terms: D002315:Cardiopulmonary Bypass; D005112:Extracorporeal Circulation; D006801:Humans; D007610:Kallikreins / Q000378:metabolism*; D018375:Neutrophil Activation; D015539:Platelet Activation; D013917:Thrombin / Q000378:metabolism*
chemical_list: D007610:Kallikreins; D013917:Thrombin